United States· US:50090-2193_cab55702-5aa0-48a9-9989-36255bffb0e4
TOUJEO
A insulin glargine product containing insulin glargine, registered in United States by A-S Medication Solutions. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Insulin glargine is registered in 13 of 19 countries.
Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Insulin glargine · ATC A10AE04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- INSULIN GLARGINE
- Manufacturer
- A-S Medication Solutions
- Country
- United States (US)
- ATC code
- A10AE04
- ATC class
- Insulin glargine
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1150090-2193-0
- ndc1150090219303 SYRINGE in 1 CARTON (50090-2193-0) / 1.5 mL in 1 SYRINGE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
433 interactions on record for insulin glargine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin glargine · interactions on record
433 records
- 15 severe
- 367 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin glargine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABASAGLAREli Lilly Nederland B.V., Utrecht
- United KingdomAbasaglar 100units/ml solution for injection 3ml cartridgesEli Lilly and Company Ltd
- BelgiumAbasaglar 100 U/mlEli Lilly Nederland
- FinlandABASAGLAREli Lilly Nederland B.V.
- SpainABASAGLAR 100 UNIDADES/ML KWIKPEN SOLUCION INYECTABLE EN PLUMA PRECARGADAEli Lilly Nederland B.V.
- IrelandABASAGLAR 100 units/mL solution for injection in a cartridgeEli Lilly Nederland B.V.
- SwedenABASAGLAR 100 enheter/ml Injektionsvätska, lösning i cylinderampullEli Lilly Nederland B.V.
- CanadaBASAGLARELI LILLY CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abasaglar, Abasaglar Kwikpen
- Liechtenstein · Abasaglar, Abasaglar Kwikpen
- Norway · Lantus, Lantus Solostar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af1c0a99-3df7-45e7-a4fa-45816437c73c GET /v1/drugs/af1c0a99-3df7-45e7-a4fa-45816437c73c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "300",
"substance": "INSULIN GLARGINE",
"productndc": "50090-2193",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "U/mL",
"application_number": "BLA206538",
"marketing_category": "BLA"
}See everything about insulin glargine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.